Roche’s BTK inhibitor may have reached ‘holy grail’ of brain penetration in phase 2 MS trial – FierceBiotech

by

  1. Roche’s BTK inhibitor may have reached ‘holy grail’ of brain penetration in phase 2 MS trial FierceBiotech
  2. Mesenchymal Stem Cell Therapy Shows Cognitive and Biomarker Improvements in Multiple Sclerosis Neurology Live
  3. Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Yahoo Finance
  4. Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data FierceBiotech
  5. Merck presents new Evobrutinib data at ECTRIMS | Merck Merck KGaA
  6. View Full Coverage on Google News

Read original article here

Leave a Comment